1 min read
Sanofi, Pfizer & Bristol Drugs Among the 12 Approvals to Look Out for in Q4
The end of the year should see a flurry of new products reaching the market to break new commercial ground or shake up their respective therapeutic
Tag : National Blog Main
1 min read
1 min read
Vertex Stops Test of Rare Disease Drug, Dimming Pipeline Prospects
Vertex Pharmaceuticals is halting work on an experimental drug for a rare protein deficiency after safety problems were reported in Phase 2
1 min read
Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin
Codiak BioSciences now has $82.5 million to fund clinical tests of a new class of medicines based on exosomes, tiny bubbles formed by cells that the
6 min read
Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin
Codiak BioSciences now has $82.5 million to fund clinical tests of a new class of medicines based on exosomes, tiny bubbles formed by cells that the
1 min read
Roche Enlists Dyno to Bring AI to Next-Generation Liver, CNS Gene Therapies
Roche made a splash with its acquisition of Spark Therapeutics, whose Luxturna, a gene therapy for an inherited form of vision loss, was the first
1 min read
Despite Phase 2 Failure, Gossamer Bio Sees a Path for Drug in Asthma
Gossamer Bio’s lead drug, an experimental treatment for asthma and allergies, has failed in two mid-stage clinical trials but the biotech sees
6 min read
Despite Phase 2 Failure, Gossamer Bio Sees a Path for Drug in Asthma
Gossamer Bio’s lead drug, an experimental treatment for asthma and allergies, has failed in two mid-stage clinical trials but the biotech sees
6 min read
Despite Phase 2 Failure, Gossamer Bio Sees a Path for Drug in Asthma
Gossamer Bio’s lead drug, an experimental treatment for asthma and allergies, has failed in two mid-stage clinical trials but the biotech sees
1 min read
SQZ Biotech Lines Up an IPO on the NYSE to Fund Cell Therapy R&D
SQZ Biotechnologies, which already has an alliance with Roche focused on developing new cancer cell therapies, is now looking to sell shares to the
5 min read
SQZ Biotech Lines Up an IPO on the NYSE to Fund Cell Therapy R&D
SQZ Biotechnologies, which already has an alliance with Roche focused on developing new cancer cell therapies, is now looking to sell shares to the
6 min read
SQZ Biotech Lines Up an IPO on the NYSE to Fund Cell Therapy R&D
SQZ Biotechnologies, which already has an alliance with Roche focused on developing new cancer cell therapies, is now looking to sell shares to the
1 min read
“Opioid Stacking” Concerns Lead FDA to Reject Avenue Therapeutics Drug
An opioid that Avenue Therapeutics reformulated for treating post-surgical pain in hospital settings has been rejected by the FDA due to safety
6 min read
“Opioid Stacking” Concerns Lead FDA to Reject Avenue Therapeutics Drug
An opioid that Avenue Therapeutics reformulated for treating post-surgical pain in hospital settings has been rejected by the FDA due to safety
1 min read
FDA Panel Vote Weighs in Favor of Alkermes Psych Drug, With Caveats
An Alkermes antipsychotic treatment designed to offer the benefits of a commonly prescribed medicine, but without the weight gain side effect, won
6 min read
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
It’s October: a time of days growing shorter, leaves changing color, and phone calls in the wee hours that rouse scientists from slumber notifying